Personalized radiation shows promise for slowing neuroendocrine tumor growth
NCT ID NCT02743741
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 18 times
Summary
This study tests a treatment called Lu-DOTATATE, which delivers radiation directly to neuroendocrine tumor cells. About 195 people with tumors that have a specific marker (somatostatin receptors) will receive up to 4 cycles of this therapy, with doses adjusted for each person. The main goal is to see how many patients remain cancer-free 12 months after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada
-
London Health Sciences Centre
London, Ontario, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
-
Sunnybrook Odette Cancer Center
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.